Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease

罗替戈汀 运动障碍 左旋多巴 相伴的 医学 帕金森病 安慰剂 透皮贴片 麻醉 内科学 透皮 疾病 药理学 替代医学 病理
作者
Nir Giladi,L. Ghys,Erwin Surmann,Babak Boroojerdi,Joseph Jankovic
出处
期刊:Parkinsonism & Related Disorders [Elsevier BV]
卷期号:20 (12): 1345-1351 被引量:24
标识
DOI:10.1016/j.parkreldis.2014.09.016
摘要

Purpose In two 6-month, double-blind, placebo-controlled studies, rotigotine transdermal system was well-tolerated and efficacious monotherapy in early-stage PD. This post hoc analysis of the long-term open-label extensions (NCT00594165; NCT00599196) of these studies assessed incidence and severity of dyskinesia in participants treated with rotigotine, with or without concomitant levodopa, for up to 6 years. Methods Open-label rotigotine was titrated to optimal dose (≤16 mg/24 h). Concomitant levodopa was permitted. Dyskinesia data, recorded using the Unified Parkinson's Disease Rating Scale Part IV, were pooled from the two open-label studies. Results Of 596 participants who received open-label rotigotine, 299 (50%) remained at trial closure; no patient discontinued due to dyskinesia. In the two studies, median exposure to rotigotine was 1910 days (∼5 years, 3 months), and 1564.5 days (∼4 years, 3 months). During up to 6 years of open-label rotigotine, 423/596 (71%) received levodopa. Dyskinesias were reported in 115/596 (19%) participants, 90/115 (78%) of who developed dyskinesia after levodopa was added; 25 reported dyskinesia in the absence of levodopa (includes patients who never received open-label levodopa, and those who reported dyskinesia before starting concomitant levodopa). Dyskinesia severity data were available for 107 of the 115 participants. In 56/107 (52%) participants, dyskinesia was considered ‘not disabling’ for all occurrences; the worst-case severity was ‘mildly disabling’ for 33/107 (31%), and ‘moderately’ or ‘severely disabling’ for 18/107 (17%; 3% of total participants). Conclusion During treatment with rotigotine in patients with PD for up to 6 years the incidence of dyskinesia was low, and the dyskinesia was generally ‘not disabling’ or ‘mildly disabling’.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
gsj完成签到,获得积分10
1秒前
2秒前
3秒前
秋天完成签到,获得积分10
4秒前
淡定的惜关注了科研通微信公众号
7秒前
Zhy发布了新的文献求助10
7秒前
8秒前
蛋挞完成签到,获得积分10
10秒前
李健应助Junning采纳,获得10
12秒前
12秒前
tingting9发布了新的文献求助10
13秒前
14秒前
爆米花应助mark采纳,获得10
15秒前
15秒前
爱看文献的小恐龙完成签到,获得积分10
16秒前
小饼干完成签到 ,获得积分10
18秒前
萧瑟处完成签到 ,获得积分10
19秒前
19秒前
20秒前
孙燕应助鹤鸣采纳,获得30
21秒前
22秒前
loski发布了新的文献求助10
24秒前
随便不放假完成签到 ,获得积分10
25秒前
淡定的惜发布了新的文献求助10
27秒前
威武的亦绿完成签到,获得积分10
27秒前
木丁完成签到,获得积分10
28秒前
28秒前
31秒前
量子星尘发布了新的文献求助30
33秒前
孙燕应助成就山河采纳,获得10
34秒前
35秒前
领导范儿应助幸福大白采纳,获得30
36秒前
谓风发布了新的文献求助10
36秒前
37秒前
q1356478314应助天白采纳,获得10
37秒前
Hanni完成签到 ,获得积分10
37秒前
38秒前
yixiaolou发布了新的文献求助10
38秒前
Junning发布了新的文献求助10
39秒前
40秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989406
求助须知:如何正确求助?哪些是违规求助? 3531522
关于积分的说明 11254187
捐赠科研通 3270174
什么是DOI,文献DOI怎么找? 1804901
邀请新用户注册赠送积分活动 882105
科研通“疑难数据库(出版商)”最低求助积分说明 809174